Photoablation increases refractive index of stroma

Photoablation increases the refractive index of the stroma following laser in situ keratomileusis (LASIK) surgery, according to a study published in the July 2008 issue of the Journal of Cataract and Refractive Surgery.

Photoablation increases the refractive index of the stroma following laser in situ keratomileusis (LASIK) surgery, according to a study published in the July 2008 issue of the Journal of Cataract and Refractive Surgery.

Sudi Patel, PhD of Practitioner Services, CSA, NHS Scotland, Edinburgh, UK and colleagues performed LASIK in 49 subjects (76 eyes) using either a microkeratome (M2; Moria) or a femtosecond laser (IntraLase; AMO). Patients undergoing surgery with a microkeratome (57 eyes) had a mean pre-surgical refractive index of 1.366±0.0049 SD; those treated with the femtosecond laser (19 eyes), 1.374±0.0047. After lifting the flap, the team measured the refractive index of the stroma before and immediately after photoablation.

Postoperatively, the mean refractive index of the microkeratome group was 1.382±0.0066; in the femtosecond group, it was 1.391±0.0102. Following ablation, both groups demonstrated a statistically significant increase in refractive index. A longer treatment time was associated with a greater increase in the refractive index.

Thus the researchers concluded that photoablation increases the refractive index of the stroma and that there exists a linear correlation between treatment time and the magnitude of refractive index improvement.

Related Videos
Trukera Medical rebranding ushers in new era of expansion into cornea market
Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL
Investigating better indications and outcomes in laser refractive surgery
Avoiding errors when converting to DMEK
EDOF lens tech is evolving to help more patients with intermediate vision
Fixoflex ring: Prof. Pallikaris describes how to utilise the device during IOL implantation
Related Content
© 2023 MJH Life Sciences

All rights reserved.